IQV - IQVIA
197.27
| Index: | S&P 500 | P/E: | 25.87 | EPS (ttm): | 7.62 | Insider Own: | 0.83% | Shs Outstand: | 181.60M | Perf Week: | -0.90% |
| Market Cap: | 36.88B | Forward P/E: | 16.50 | EPS next Y: | 11.96 | Insider Trans: | -0.08% | Shs Float: | 180.00M | Perf Month: | 1.49% |
| Income(ttm): | 1.41B | PEG: | 2.74 | EPS next Q: | 3.11 | Inst Own: | 92.94% | Short Float: | 1.73% | Perf Quarter: | -18.05% |
| Revenue(ttm): | 15.31B | P/S: | 2.41 | EPS this Y: | 9.01% | Inst Trans: | 2.69% | Short Ratio: | 2.03 | Perf Half Y: | -7.86% |
| Book/sh: | 38.36 | P/B: | 5.14 | EPS next Y: | 7.54% | ROA: | 5.29% | Short Interest: | 3.11M | Perf Year: | -12.32% |
| Cash/sh: | 9.16 | P/C: | 21.54 | EPS next 5Y: | 9.43% | ROE: | 22.00% | 52W Range: | 187.62 - 261.73 | Perf YTD: | -14.74% |
| Dividend Est.: | - | P/FCF: | 18.81 | EPS past 5Y: | 42.42% | ROI: | 7.22% | 52W High: | -24.63% | Beta: | 1.48 |
| Dividend TTM: | - | Quick Ratio: | 0.81 | Sales past 5Y: | 7.76% | Gross Margin: | 27.81% | 52W Low: | 5.14% | ATR (14): | 5.76 |
| Dividend Ex-Date: | - | Current Ratio: | 0.81 | EPS Y/Y TTM: | 27.69% | Oper. Margin: | 14.13% | RSI (14): | 43.68 | Volatility: | 3.11% 2.56% |
| Employees: | 87000 | Debt/Eq: | 1.97 | Sales Y/Y TTM: | 3.17% | Profit Margin: | 9.17% | Recom: | 1.43 | Target Price: | 247.77 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 1.79 | EPS Q/Q: | -5.28% | Payout: | 0.00% | Rel Volume: | 2.19 | Prev Close: | 191.52 |
| Sales Surprise: | 0.79% | EPS Surprise: | 0.56% | Sales Q/Q: | 4.06% | Earnings: | Oct 31 BMO | Avg Volume: | 1.53M | Price: | 197.27 |
| SMA20: | -1.39% | SMA50: | -5.81% | SMA200: | -13.35% | Undervalued: 25.6% | Volume: | 3,345,871 | Change: | 3.00% | |
Graham Classic formula value: 187.21
(P/E=8 * 1g) Min value: 119.26
(current P/E * 2g) Max value: 306.06
Average value: 204.18
IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.